5 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 10 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 5, Completed 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow Plasmablastic Lymphoma: new trials by email Literature Review of Plasmablastic Lymphoma trials Research Report on Plasmablastic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV Elranatamab (Elra) - Plasmablastic Lymphoma, HIV | Phase 1 | Recruiting | University of Illinois at Chicago | 17 | 2026-10-21 | 2026-10-26 |
| RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies Allogeneic CAR-T - Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 27 | 2025-08-01 | 2025-08-13 |
| Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Vincristine, Prednisone, Doxorubicin - Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 25 | 2023-06-27 | 2026-08-25 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies XmAb13676 - B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Xencor, Inc. | 154 | 2016-10-01 | 2024-11-13 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2010-10-06 | 2023-11-21 |
Burkitt Lymphoma (6) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Primary Effusion (4) · Lymphoma, B-Cell (3) · Lymphoma, Mantle-Cell (3) · HIV Infections (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Pyloric Stenosis, Hypertrophic (2) · Waldenstrom Macroglobulinemia (2) · Epstein-Barr Virus Infections (1) · Hodgkin Disease (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoma (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Infections (7) · Lymphoma, B-Cell (7) · Virus Diseases (7) · DNA Virus Infections (6) · Herpesviridae Infections (6) · Lymphoma, Non-Hodgkin (6) · Tumor Virus Infections (6)
Cyclophosphamide (4) · Doxorubicin (4) · Etoposide (4) · Prednisone (4) · Rituximab (4) · Vincristine (4) · deltacortene (3) · prednylidene (3) · CT-P10 (2) · Cytarabine (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Biopsy (1) · Carmustine (1) · Hydrocortisone (1)
National Cancer Institute (NCI) (4) · AIDS Malignancy Consortium (1) · Northwestern University (1) · Schrödinger, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Illinois at Chicago (1) · Xencor, Inc. (1)
United States (9) · France (2) · China (1) · Italy (1) · Moldova (1) · Poland (1) · Romania (1) · South Korea (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Barbara Pro, MD (1) · Chet Bohac, PharmD, MD, MSc (1) · Frank G Basile, M.D. (1) · James Godfrey (1) · Juan C Ramos (1) · Lei Fan (1) · Mehrdad Abedi (1) · Paul Rubinstein, MD (1) · Ramya M Ramaswami, M.D. (1) · Stefan K Barta (1)
UM1CA121947 (2), P30CA060553 (1), U01CA121947 (1), UM1CA186717 (1)